TIDMCOG

RNS Number : 9994T

Cambridge Cognition Holdings PLC

28 July 2022

Cambridge Cognition Holdings Plc

(" Cambridge Cognition" or the "Company")

Cambridge Cognition wins PTSD trials with top 10 pharmaceutical company

and the United States Department of Defense

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce two agreements in a new therapeutic area for the Company, post-traumatic stress disorder ("PTSD"). Most recently, a research agreement was entered into with the with the United States Department of Defense, following on from a contract secured earlier this year with a top 10 pharmaceutical company. Approximately 20 PTSD treatment trials run every year(1) , demonstrating the potential for further sales in this therapeutic area.

PTSD affects around 15 million adults a year(2) and up to 31% of veterans, many of whom do not experience relief from their symptoms with existing medications. It has been suggested that the symptoms of PTSD could directly lead to deficits in executive functioning, including re-experiencing memories, problems with concentration, and hyperarousal interrupting working memory performance(3) .

Only two pharmacological treatments for PTSD have received FDA-approval. One reason for this could be that drug response is highly variable between affected individuals, making it difficult to develop effective treatments. In efforts to address the therapeutic need, the United States Department of Defense is developing a precision medicine approach to PTSD. Cambridge Cognition has been selected as a cognitive assessment provider for the project because CANTAB(TM) offers accurate measurement of the potentially distinct pathophysiological processes involved in PTSD.

Pharmaceutical companies are also investigating the potential for new drug classes for PTSD. Recently, a top 10 pharmaceutical company has contracted with Cambridge Cognition to be their cognitive assessment partner for an upcoming PTSD treatment trial. In delivering the contract, Cambridge Cognition will provide its proprietary cognitive assessment tool, CANTAB(TM) , as an exploratory endpoint.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"Cognitive impairment is increasingly recognised as a major component of PTSD. At Cambridge Cognition, we are pleased to be providing the company's expertise to monitor cognitive symptoms with a view to improving outcomes for those suffering from the after-effects of major trauma."

For further information, contact:

 
 Cambridge Cognition Holdings Plc               Tel: 012 2381 0700 
  Matthew Stork, Chief Executive Officer         press@camcog.com 
  Stephen Symonds, Chief Financial Officer 
 Panmure Gordon (UK) Limited (NOMAD and Joint   Tel: 020 7886 2968 
  Broker)                                        (Corporate Finance) 
  Freddy Crossley / Emma Earl                    (Corporate Broking) 
  Rupert Dearden 
 Dowgate Capital Limited (Joint Broker)         Tel: 020 3903 7715 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)         Tel: 020 3934 6630 
  Tim Metcalfe / Graham Herring / Zach Cohen

References

   1.    TrialTrove search of PhI - IV PTSD Trials 2011 - 2021 
   2.    US Department of Veteran Affairs. https://www.ptsd.va.gov/understand/common/common_adults.asp

3. Vasterling, J. J., Duke, L. M., Brailey, K., Constans, J. I., Allain, A. N., Jr., & Sutker, P. B. (2002). Attention, learning, and memory performances and intellectual resources in Vietnam veterans: PTSD and no disorder comparisons. Neuropsychology, 16, 5-14.

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDZGZNLNKGZZM

(END) Dow Jones Newswires

July 28, 2022 02:00 ET (06:00 GMT)

Grafico Azioni Cambridge Cognition (AQSE:COG.GB)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Cambridge Cognition
Grafico Azioni Cambridge Cognition (AQSE:COG.GB)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Cambridge Cognition